Journal
CELL STEM CELL
Volume 10, Issue 6, Pages 740-749Publisher
CELL PRESS
DOI: 10.1016/j.stem.2012.05.010
Keywords
-
Categories
Funding
- NIH [R24DK092760, UO1-HL100001, RC4-DK090913, P50HG005550]
- ARRA [RC2-HL102815]
- Roche Foundation for Anemia Research
- Alex's Lemonade Stand
- Ellison Medical Foundation
- Doris Duke Medical Foundation
- Harvard Stem Cell Institute
Ask authors/readers for more resources
Stem cells are the seeds of tissue repair and regeneration and a promising source for novel therapies. However, apart from hematopoietic stem cell (HSC) transplantation, essentially all other stem cell treatments remain experimental. High hopes have inspired numerous clinical trials, but it has been difficult to obtain unequivocal evidence for robust clinical benefit. In recent years, unproven therapies have been widely practiced outside the standard clinical trial network, threatening the cause of legitimate clinical investigation. Numerous challenges and technical barriers must be overcome before novel stem cell therapies can achieve meaningful clinical impact.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available